Guerrero Patrícia, Fuchs Flávio D, Moreira Leila M, Martins Vítor M, Bertoluci Carolina, Fuchs Sandra C, Gus Miguel
Graduate Study Program in Health Sciences-Cardiology, Universidade Federal do Rio Grande do Sul (UFRGS), Brazil.
Clin Exp Hypertens. 2008 Oct;30(7):553-64. doi: 10.1080/10641960802441906.
A large proportion of patients with hypertension need a second drug to reach satisfactory control of blood pressure (BP), but there are few well-designed controlled trials comparing the efficacy of drugs added as a second option. In a double-blind randomized clinical trial, 82 patients with uncontrolled BP, receiving hydrochlorothiazide 25 mg daily, were selected to receive amiloride 2.5-5 mg/day (n = 39) or enalapril 10-20 mg/day (n = 43). Ambulatory blood pressure monitoring (ABPM) was done before and after 12-weeks of treatment. Office BP was measured in the 4(th), 8(th), and 12(th) weeks. The doses of amiloride and enalapril were doubled in the fourth week, and propranolol was added in the 8th week if office BP was above 140/90 mm Hg. There was a greater BP reduction in patients treated with enalapril. The ABPM delta values between the groups were 3.6 +/- 2.2, 3.9 +/- 2.2, and 1.1 +/- 2.7 mmHg for 24-h, daily, and nightly systolic blood pressure, respectively, favoring enalapril. For diastolic blood pressure (DBP), the deltas were 1.7 +/- 2.0, 3.2 +/- 1.5, and 1.2 +/- 1.9 mmHg, respectively (p = 0.039 for daily DBP). Office SBP decreased more and sooner in patients allocated to enalapril (p = 0.003). More patients taking amiloride required propranolol to control BP (p = 0.035). Potassium increased 0.3 mEq/L on the average in both groups. Cough, albeit predominantly mild, was reported more frequently by participants treated with enalapril. We conclude that enalapril is more effective than amiloride to lower BP of patients on hydrochlorothiazide with uncontrolled BP.
很大一部分高血压患者需要加用第二种药物才能使血压得到满意控制,但比较作为第二种选择加用药物疗效的精心设计的对照试验很少。在一项双盲随机临床试验中,选取82例血压控制不佳、每日服用25 mg氢氯噻嗪的患者,分别接受每日2.5 - 5 mg阿米洛利(n = 39)或每日10 - 20 mg依那普利(n = 43)治疗。在治疗12周前后进行动态血压监测(ABPM)。在第4、8和12周测量诊室血压。阿米洛利和依那普利的剂量在第4周加倍,如果诊室血压高于140/90 mmHg,则在第8周加用普萘洛尔。接受依那普利治疗的患者血压降低幅度更大。两组间24小时、日间和夜间收缩压的ABPM差值分别为3.6±2.2、3.9±2.2和1.1±2.7 mmHg,依那普利组更优。对于舒张压(DBP),差值分别为1.7±2.0、3.2±1.5和1.2±1.9 mmHg(日间DBP,p = 0.039)。分配到依那普利组的患者诊室收缩压下降更多、更快(p = 0.003)。更多服用阿米洛利的患者需要加用普萘洛尔来控制血压(p = 0.035)。两组血钾平均升高0.3 mEq/L。依那普利治疗的参与者更频繁地报告咳嗽,尽管主要为轻度咳嗽。我们得出结论,对于服用氢氯噻嗪后血压控制不佳的患者,依那普利在降低血压方面比阿米洛利更有效。